Andy Rawstron

10PUBLICATIONS
99CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Cardiovascular medicine and haematology not elsewhere classifiedMedical mycologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

David J Allsup, David A Cairns, E Faye Samy

|Nov 12, 2025
COVID-19-related mortality in a real-world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK's Haematological Malignancy Research Network.

Alexandra Smith, Clare Frobisher, Abraham Varghese

|Jun 22, 2022
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos

|Apr 04, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.

Ruth M de Tute, Charlotte Pawlyn, David A Cairns

|May 12, 2019
Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells.

Katie B Holmes, Ildar I Sadreev, Andy C Rawstron

|Feb 01, 2019
Telomere length predicts for outcome to FCR chemotherapy in CLL.

Kevin Norris, Peter Hillmen, Andrew Rawstron

Pageof 2

Frequent Collaborators

3 joint publications

Reuben Tooze

2 joint publications

David J Allsup

2 joint publications

Rita Alaggio

2 joint publications

Catalina Amador